Nomura estimates that Hansoh Pharma (03692) will see a YoY increase of 38.2% and 86.1% in revenue and profit in the first half of the year.
Zhongtong Finance app learned that Nomura released a research report stating that the target price for Hansoh Pharma (03692) has been raised from HKD 15.03 to HKD 17.23, maintaining a "neutral" rating. The company's revenue and profit forecast for this year have been raised by 2.7% and 6.9%, respectively, while those for next year have been raised by 6% and 0.7%, in order to reflect the performance of antibody-drug conjugates (ADC) in the first half of the year, as well as the expected progress of Amertonertinib, offsetting the sales pressure of non-patented drugs. The bank estimates that the company will see a YoY increase of 38.2% and 86.1% in revenue and profit in the first half of the year.
